Three-Pronged attack on prostate cancer tested in new trial
NCT ID NCT06528210
Summary
This study aimed to test a combination of three treatments for men with high-risk prostate cancer that has not spread. The approach combined a drug to boost the immune system (pembrolizumab) with standard hormone-blocking therapy and radiation. The goal was to see if this combination could more effectively kill cancer cells and reduce the chance of the cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I PROSTATE CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.